SLS
SELLAS Life Sciences Group, Inc · Healthcare · Biotechnology
$10.38
-14.71% today · -14.50% 1W
Oct 28 close or latest
After hours $10.38 0.00% ·
SLS against the S&P 500 components
| Window | Rank of 500 | Every S&P 500 stock · SLS SPY | Gain | SPY gain |
|---|---|---|---|---|
| 1 day | #501 | -14.71% | +0.34% | |
| 1 week | #499 | -14.50% | -0.10% | |
| 1 month | #467 | -10.44% | +0.88% | |
| 3 months | #178 | +2.87% | +4.50% | |
| 6 months | #8 | +112.70% | +9.07% | |
| 1 year | #3 | +419.00% | +13.62% | |
| Overall | #318 | sum of the six window ranks, ranked again | ||
R500 ranks the stock's gain over each window against the S&P 500 components over the same window (#1 = best). Each grey dot is one component, by its gain (the most extreme 1% at each end are pinned to the edge); hover a row for the numbers. Near-real-time during market hours.
Biotechnology S&P 500 industry · 6 stocks · SLS #4 of 6 over 3 months
| Stock | 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|---|
| MRNA Moderna | +3.0% | -12.9% | +8.6% | +283.8% | +354.3% | +744.8% |
| REGN Regeneron Pharmaceuticals | -0.3% | +0.9% | +8.1% | +17.1% | +11.4% | +24.9% |
| VRTX Vertex Pharmaceuticals | +1.7% | +1.0% | +0.4% | +8.0% | +23.1% | +25.4% |
| TECH Bio-Techne | +0.1% | +0.1% | +0.2% | +1.0% | +36.2% | +14.3% |
| INCY Incyte | +0.2% | +3.0% | -6.4% | -10.1% | +19.6% | +27.5% |
| SLS | -14.7% | -14.5% | -10.4% | +2.9% | +112.7% | +419.0% |
| Others' average | +0.9% | -1.6% | +2.2% | +60.0% | +88.9% | +167.4% |
| SLS's place | #6 of 6 | #6 of 6 | #6 of 6 | #4 of 6 | #2 of 6 | #2 of 6 |
Click a column to sort.
Fundamentals Biotechnology
| Metric | Value | Industry median | S&P 500 median | Rank in S&P 500 | Rank in industry |
|---|---|---|---|---|---|
| Targeted Gain Median higher is better | 215.0% | 8.2% | 14.1% | #1 of 498 | #1 of 6 |
| fPE/tPE lower is better | — | 0.75 | 0.76 | — | — |
| PE/G lower is better | — | 2.07 | 1.54 | — | — |
| EV/Revenue lower is better | — | 9.39 | 3.88 | — | — |
| Gross Margin higher is better | 0.0% | 55.0% | 45.6% | #482 of 483 | #5 of 6 |
| Profit Margin higher is better | 0.0% | 27.7% | 13.2% | #477 of 501 | #5 of 6 |
| Revenue Growth higher is better | — | 12.5% | 8.9% | — | — |
Hover a metric for what it measures. Ranks and medians are over the S&P 500 components with a value, the stock included in the ranks (#1 = best); for the three ratios only positive values count, as a negative ratio means no earnings.